Fea Antonio M

Hydrus microstent compared to selective laser trabeculoplasty in primary open angle glaucoma: one year results.

Both SLT and Hydrus implantation reduced IOP without serious adverse events. Hydrus implantation led to a significant and further reduction in medication dependence at 12 months.

European study of the efficacy of a cross-linked gel stent for the treatment of glaucoma.

Insertion of a cross-linked gel stent alone or combined with phacoemulsification might be effective and safe in the treatment of open-angle glaucoma, with a substantial reduction in IOP and number of medications.

Evaluation of a Schlemm canal scaffold microstent combined with phacoemulsification in routine clinical practice: Two-year multicenter study.

This microstent combined with cataract surgery safely and effectively reduced the IOP and medication use in a routine clinical practice setting with results comparable to those in previously published controlled clinical trials.

Two-Year Performance and Safety Results of the MINIject Supraciliary Implant in Patients With Primary Open-Angle Glaucoma: Meta-Analysis of the STAR-I, II, III Trials.

This meta-analysis demonstrates the favorable safety and efficacy profile of a supraciliary device implanted in a stand-alone, ab-interno procedure in patients with mild-to-moderate POAG.

Glaucoma Surgery Comparison: SIBS Microshunt Versus Gelatin 45 µm Microstent Versus Trabeculectomy as Primary Surgical Interventions.

Overall, patients with the SIBS microshunt achieved higher success rates compared to both trabeculectomy and the gelatin 45 μm microstent group, with fewer postoperative complications, interventions, and reoperations for glaucoma.

Outcomes of the 63-μm Gelatin Microstent Versus 45-μm Gelatin Microstent: An International Multicenter Study.

Xen63 demonstrated superior IOP-lowering effectiveness compared with its 45-μm variant in patients requiring more robust IOP targets.